Novocuff

Novocuff, Inc. is a medical device company focused on improving pregnancy outcomes and reducing preterm births caused by Preterm Premature Rupture of Membranes (PPROM) and cervical shortening. The company has developed the Novocuff Cervical Control System (CCS), a device designed to stabilize and close the cervix, retain amniotic fluid, and sustain cervical length with the goal of extending pregnancy. This approach aims to address PPROM and cervical shortening, which are major contributors to preterm birth. Preterm birth, defined as delivery before 37 weeks of gestation, is a leading cause of infant death globally. According to the World Health Organization, preterm birth complications were responsible for approximately 1 million deaths in 2020. PPROM occurs in approximately 1%-4% of all pregnancies, with its incidence reaching as high as 13.9% in developing countries, as reported in a 2022 study. Founded in 2021, Novocuff is headquartered in Mountain View, California. The company has initiated two first-in-human clinical studies to investigate the device's effectiveness in treating PPROM and cervical shortening. Novocuff plans to begin a multi-center US pivotal clinical trial in early 2025 to further evaluate the device's efficacy and safety.

Key customers and partnerships

Novocuff has received support from several notable organizations in the healthcare and investment sectors. In July 2024, Laborie Medical Technologies Corp., a diagnostic and therapeutic medical technology company, invested in Novocuff. This partnership aligns with both companies' missions to improve healthcare for pregnant women and newborns worldwide. Additionally, Novocuff has garnered support from other prominent entities such as AXA IM Alts, Laerdal Million Lives Fund, RH Capital, Avestria Ventures, and March of Dimes, which participated in the company's Series A financing round in July 2024.